Literature DB >> 22806541

Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.

Gunther Boysen1, Damaris Bausch-Fluck, Claudio R Thoma, Anna M Nowicka, Daniel P Stiehl, Igor Cima, Van-Duc Luu, Adriana von Teichman, Thomas Hermanns, Tullio Sulser, Barbara Ingold-Heppner, Niklaus Fankhauser, Roland H Wenger, Wilhelm Krek, Peter Schraml, Bernd Wollscheid, Holger Moch.   

Abstract

The identification of cell surface accessible biomarkers enabling diagnosis, disease monitoring, and treatment of renal cell carcinoma (RCC) is as challenging as the biology and progression of RCC is unpredictable. A hallmark of most RCC is the loss-of-function of the von Hippel-Lindau (pVHL) protein by mutation of its gene (VHL). Using the cell surface capturing (CSC) technology, we screened and identified cell surface N-glycoproteins in pVHL-negative and positive 786-O cells. One hundred six cell surface N-glycoproteins were identified. Stable isotope labeling with amino acids in cell culture-based quantification of the CSC screen revealed 23 N-glycoproteins whose abundance seemed to change in a pVHL-dependent manner. Targeted validation experiments using transcriptional profiling of primary RCC samples revealed that nine glycoproteins, including CD10 and AXL, could be directly linked to pVHL-mediated transcriptional regulation. Subsequent human tumor tissue analysis of these cell surface candidate markers showed a correlation between epithelial AXL expression and aggressive tumor phenotype, indicating that pVHL-dependent regulation of glycoproteins may influence the biologic behavior of RCC. Functional characterization of the metalloprotease CD10 in cell invasion assays demonstrated a diminished penetrating behavior of pVHL-negative 786-O cells on treatment with the CD10-specific inhibitor thiorphan. Our proteomic surfaceome screening approach in combination with transcriptional profiling and functional validation suggests pVHL-dependent cell surface glycoproteins as potential diagnostic markers for therapeutic targeting and RCC patient monitoring.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806541      PMCID: PMC3394196          DOI: 10.1596/neo.12130

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  45 in total

1.  Automated statistical analysis of protein abundance ratios from data generated by stable-isotope dilution and tandem mass spectrometry.

Authors:  Xiao-Jun Li; Hui Zhang; Jeffrey A Ranish; Ruedi Aebersold
Journal:  Anal Chem       Date:  2003-12-01       Impact factor: 6.986

2.  Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.

Authors:  A K Avery; J Beckstead; A A Renshaw; C L Corless
Journal:  Am J Surg Pathol       Date:  2000-02       Impact factor: 6.394

3.  Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.

Authors:  Jung-Hyun Min; Haifeng Yang; Mircea Ivan; Frank Gertler; William G Kaelin; Nikola P Pavletich
Journal:  Science       Date:  2002-05-09       Impact factor: 47.728

4.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

5.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma.

Authors:  Peter Schraml; Kirsten Struckmann; Florian Hatz; Stefan Sonnet; Charlotte Kully; Thomas Gasser; Guido Sauter; Michael J Mihatsch; Holger Moch
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

6.  CD10 is a diagnostic and prognostic marker in renal malignancies.

Authors:  C Langner; M Ratschek; P Rehak; L Schips; R Zigeuner
Journal:  Histopathology       Date:  2004-11       Impact factor: 5.087

7.  The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5'-untranslated region.

Authors:  Nobuo Sezaki; Fumihiko Ishimaru; Takayuki Tabayashi; Itaru Kataoka; Koichi Nakase; Keiko Fujii; Teruhiko Kozuka; Hiroyuki Nakayama; Mine Harada; Mitsune Tanimoto
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

8.  Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression.

Authors:  Peter Schraml; Alexander Hergovich; Florian Hatz; Mahul B Amin; So D Lim; Wilhelm Krek; Michael J Mihatsch; Holger Moch; Alexander Hergovitz
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL.

Authors:  Alexander Hergovich; Joanna Lisztwan; Robert Barry; Pia Ballschmieter; Wilhelm Krek
Journal:  Nat Cell Biol       Date:  2003-01       Impact factor: 28.824

10.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.

Authors:  John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

View more
  22 in total

1.  Renal tumors: diagnostic and prognostic biomarkers.

Authors:  Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J Merino; George Netto; Victor E Reuter; Steven S Shen; David J Grignon; Rodolfo Montironi; Lars Egevad; John R Srigley; Brett Delahunt; Holger Moch
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 4.  [Renal cancer biomarkers. What is justified?].

Authors:  H Moch
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 5.  Biomarkers in renal cancer.

Authors:  Holger Moch; John Srigley; Brett Delahunt; Rodolfo Montironi; Lars Egevad; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 6.  Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Nizar M Tannir; Sumanta K Pal; Michael B Atkins
Journal:  Oncologist       Date:  2018-02-27

7.  IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors.

Authors:  Hailong Ruan; Zhengshuai Song; Qi Cao; Dong Ni; Tianbo Xu; Keshan Wang; Lin Bao; Junwei Tong; Haibing Xiao; Wen Xiao; Gong Cheng; Zhiyong Xiong; Huageng Liang; Di Liu; Liang Wang; Tredan Olivier; Boyle Helen Jane; Hongmei Yang; Xiaoping Zhang; Ke Chen
Journal:  Mol Ther       Date:  2020-03-10       Impact factor: 11.454

8.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

9.  A mass spectrometric-derived cell surface protein atlas.

Authors:  Damaris Bausch-Fluck; Andreas Hofmann; Thomas Bock; Andreas P Frei; Ferdinando Cerciello; Andrea Jacobs; Hansjoerg Moest; Ulrich Omasits; Rebekah L Gundry; Charles Yoon; Ralph Schiess; Alexander Schmidt; Paulina Mirkowska; Anetta Härtlová; Jennifer E Van Eyk; Jean-Pierre Bourquin; Ruedi Aebersold; Kenneth R Boheler; Peter Zandstra; Bernd Wollscheid
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

10.  Destruction of a distal hypoxia response element abolishes trans-activation of the PAG1 gene mediated by HIF-independent chromatin looping.

Authors:  Alexandra Schörg; Sara Santambrogio; James L Platt; Johannes Schödel; Maja T Lindenmeyer; Clemens D Cohen; Katrin Schrödter; David R Mole; Roland H Wenger; David Hoogewijs
Journal:  Nucleic Acids Res       Date:  2015-05-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.